USPTO published a patent application for heterocyclic JAK-1 inhibitor compounds intended for veterinary therapeutic use, specifically treating canine atopic dermatitis. The application covers the compound structures, methods of preparation, and uses for treating inflammatory conditions in non-human mammals.

This is a patent publication rather than a regulatory action requiring compliance. Pharmaceutical companies and drug manufacturers developing JAK inhibitors or veterinary dermatology treatments may wish to review the claims to assess potential freedom-to-operate considerations or licensing opportunities. No compliance deadlines, penalties, or reporting requirements apply to this document.